Efficacy Study of an Anti-Tumor Necrosis Factor (TNF) Alpha Agent in Patients With Hand Osteoarthritis (DORA)
|ClinicalTrials.gov Identifier: NCT00597623|
Recruitment Status : Completed
First Posted : January 18, 2008
Last Update Posted : July 26, 2012
Digital osteoarthritis (DO) which affects the interphalangeal joints and the Metacarpophalangeal (MCP) of the thumb is a common disease, the prevalence of which increases with age (36% of the population aged over 70). Certain forms of DO with clinical manifestations involving inflammatory features are particularly refractory to usual treatments (analgesics, NSAIDs, braces and local injections). The mechanism of osteoarthritis involves two major cytokines: interleukin-1 beta and tumor necrosis factor alpha. TNF alpha is particularly involved in the inflammation process.
The aim of the present study is to study the efficacy of TNF alpha blockers (2 injections of adalimumab compared to placebo injections in patients with severe and refractory hand osteoarthritis.
We hope that such new therapeutic option may induce substantial pain relief.
|Condition or disease||Intervention/treatment||Phase|
|Hand Osteoarthritis||Other: Adalimumab (Humira®) Other: Placebo||Phase 3|
Objective: To demonstrate the efficacy of two subcutaneous injections of anti-TNF alpha (adalimumab) in patients with DO refractory to usual treatments (NSAIDs - analgesics).
Design: Randomized placebo-controlled multicenter (20 sites (amendment 18/12/2008)) trial
Trial duration: 6 months follow-up per patient, total trial duration: 12 months
Number of patients: 84(up)
Dose of administration: Two subcutaneous injections separated by a 2-week interval of either adalimumab or placebo. Therapeutic precautions inherent to the prescription of anti-TNF alpha are based upon those recommended in rheumatoid arthritis. With only two injections of anti-TNF alpha, the risk of complications (infectious in particular) inherent to the anti-TNF alpha appears to be extremely slight.
Patient selection: Patients with digital osteoarthritis (DIP and PIP) according to American College of Rheumatology (ACR) criteria (with a recent X-ray, less than 6 months, of the hands, showing signs of digital osteoarthritis), symptomatic for more than 3 months (at least three finger joints) and scored more than 40 mm on a pain visual analog scale (VAS) despite use of a level 1 analgesic (acetaminophen: 4 g daily) andNSAIDs. Main Exclusion criteria are contraindications to anti-TNF alpha according to international guidelines.
Methods: Patients will be seen at a screening visit, then during treatment administration (W0 and W2) and at follow-up visits: W6, 10, 14 and 26. NSAIDs will be stopped at the time of screening.
Efficacy evaluation: The efficacy endpoint is improvement in pain on a pain VAS at different times of assessment (primary endpoint at W6). A more than 50% improvement, in comparison with baseline, will be considered to be significant. Secondary endpoints are: number of tender joints, number of swollen joints, morning stiffness, global assessment of handicap by patient, global assessment of handicap by physician, the DREISER'S algofunctional index, Cochin hand index, weekly evolution of pain ( patient record), and recording of analgesic use (acetaminophen or NSAIDs).
Statistical data: Statistical analysis will be performed on the inter-group difference in the intention-to-treat population. khi-2 will be used only for criteria number 1.
Anticipated result: Significant superiority of adalimumab over placebo which would provide a therapeutic solution in difficult-to-treat patients with hand OA.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||84 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Randomized Double Blind Placebo-controlled Trial of the Efficacy of an Anti-TNF Alpha Agent (Adalimumab, Humira®) in Patients With Incapacitating Hand Osteoarthritis Refractory to Usual Treatment|
|Study Start Date :||January 2008|
|Actual Primary Completion Date :||June 2010|
|Actual Study Completion Date :||December 2010|
2 injections of Adalimumab (Humira®)
Other: Adalimumab (Humira®)
syringes for injections under cutaneous dose = 40mg vol = 0.8 ml
Placebo Comparator: 2
2 injection of Placebo
syringes under cutaneous vol = 8 ml
- Level of Pain on visual analogue scale [ Time Frame: 4 weeks following the last injection ]
- Number of tender joints [ Time Frame: at weeks 4, 6, 10, 14, 26 ]
- Number of swollen joints [ Time Frame: at weeks 4, 6, 10, 14, 26 ]
- Global assessment of handicap by patient [ Time Frame: at weeks 4, 6, 10, 14, 26 ]
- Global assessment of handicap by physician [ Time Frame: at weeks 4, 6, 10, 14, 26 ]
- Duration of morning stiffness [ Time Frame: at weeks 4, 6, 10, 14, 26 ]
- DREISER'S algofunctional index [ Time Frame: at weeks 4, 6, 10, 14, 26 ]
- Cochin hand index [ Time Frame: at weeks 4, 6, 10, 14, 26 ]
- Weekly pain recording, and recording of analgesic use (acetaminophen) [ Time Frame: at weeks 4, 6, 10, 14, 26 ]
- Percentage of non responders according to the number of patients requiring NSAIDS intake during the trial and/or rule out for lack of efficacy [ Time Frame: from week 0 until week 26 ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00597623
|CHU Henri Mondor|
|Créteil, France, 94000|
|Principal Investigator:||Xavier Chevalier, PU-PH||Assistance Publique - Hôpitaux de Paris|